Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine for Cognitive Impairment in Long COVID
NCT06055244Phase 2Completed
- Sponsor
- The Ohio State University
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID-19 condition (PCC) comparing Amantadine with Placebo (2 arms). Primary endpoints: Improvement in cognitive symptoms at 4 months and Improvement on objective cognitive testing at 4 months. Started Dec 2023; status: completed.
02
Drugs
amantadine
03
Conditions
post-COVID-19 condition (PCC)
Beyond the preview
Go deeper on NCT06055244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055244.